You just read:

AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018

News provided by

AcelRx Pharmaceuticals, Inc.

Mar 08, 2018, 04:01 ET